Abstract
Background COVID-19 curve can be flattened by adopting mass screening protocols with aggressive testing and isolating infected populations. The current approach largely depends on RT-PCR/rapid antigen tests that require expert personnel resulting in higher costs and reduced testing frequency. Loss of smell is reported as a major symptom of COVID-19, however, a precise olfactory testing tool to identify COVID-19 patient is still lacking.
Methods To quantitatively check for the loss of smell, we developed an odor strip, “COVID-Anosmia checker”, spotted with gradients of coffee and lemon grass oil. We validated its efficiency in healthy and COVID-19 positive subjects. A trial screening to identify SARS-CoV-2 infected persons was also carried out to check the sensitivity and specificity of our screening tool.
Findings It was observed that COVID positive participants were hyposmic instead of being anosmic when they were subjected to smelling higher odor concentration. Our tool identified 97% of symptomatic and 94% of asymptomatic COVID-19 positive subjects after excluding most confounding factors like concurrent chronic sinusitis. Further, it was possible to reliably predict COVID-19 infection by calculating a loss of smell score with 100% specificity. We coupled this tool with a mobile application, which takes the input response from the user, and can readily categorize the user in the appropriate risk groups.
Conclusion Loss of smell can be used as a reliable marker for screening for COVID-19. Our tool can be used for first-line screening to trace out COVID-19 infection effectively. It can be used in difficult to reach geographical locations.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was an epidemiological study and it does not require clinical trial registration.
Funding Statement
This work was supported by Intramural grants to J.J. from Rajiv Gandhi Centre for Biotechnology (RGCB) and external funding from the Department of Science and Technology (SERB), Government of India (CVD/2020/001011). B.B (UGC-332486), P.A.R (CSIR-09/716(0156)/2015-EMR-I) and S.P (CSIR-09/716(0161)/2015-EMR-I) were supported by research fellowship from Government of India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Human Ethics Committee of Rajiv Gandhi Center for Biotechnology (RGCB/IHEC/250/2020/28) and Saveetha Medical College Hospital (002/08/2020/IEC/SMCH).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The title of the article is updated; The abstract is updated; The discussion part is updated; One new citation added; Figure-3 updated; Authors' contribution added.
Data Availability
We agree to make available materials, data and associated protocols used in this study upon request.
